Alexion Pharmaceuticals investing €100m into biologics facility in Athlone
US-headquartered biopharmaceutical company Alexion Pharmaceuticals is to invest €100m in a new biologics manufacturing facility in its Athlone operations which will result in the creation of 50 additional jobs. This will bring total employment at the plant to more than 100 people. The investment will see the construction of a new biologics manufacturing facility at the site.
Commenting on the announcement, Alexion’s Executive Vice President of Global Operations Julie O’Neill said: “Ireland is a key location for Alexion’s global operations and we are committed to further developing our manufacturing facilities in the country to support increasing production needs of our highly innovative and life-transforming therapies.”
Alexion has been in Athlone since 2014 and the current site there houses a vial fill-finish facility.
Alexion is also currently constructing a large-scale bulk biologics manufacturing facility at its Dublin site in College Park.
Between its facilities in Athlone and College Park, Alexion currently employs over 250 people in Ireland, and expects to continue to grow to almost 500 employees by the end of 2019.
Alexion has announced investments totalling €600 million in Ireland since 2014.
